CRYSVITA 30 mg, solution for injection bottle, 1 ml
Active ingredients: Burosumab
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injectionbottle, 1 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- CRYSVITA 30 mg, solution injectable
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 1 flacon en verre de 1 mL
- Marketing authorisation holder
- KYOWA KIRIN HOLDINGS (PAYS-BAS)
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 15 Nov 2018
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Initial prescription by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
67649597CIP73014523CIP133400930145234Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| BUROSUMABsolution | 30 mg · un flacon de 1 mL de solution | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.